The completion of the Human Genome Project will bring tremendous commercial opportunities for companies able to expedite the process of translating the human genome into new therapeutic and diagnostic products. Genomics and Drug Development: Impacts and Strategic Implications is a forthcoming study from Decision Resources, Inc., that evaluates the implications of genomics technologies for the drug industry and describes how those technologies will change the industry over the next decade.

(Photo: )

This unique study captures the insights of 33 pharmaceutical executives from 26 major pharmaceutical companies--a roster of individuals who play a significant role in determining how billions of dollars are spent in pharmaceutical R&D. In interviews we conducted in mid-2000, these executives describe industry-wide trends and strategies in this post-genomic era and provide important predictions on the future of genomics-based drug development. The result is a timely analysis of the application of genomics to drug development and the decisions involved in genomics R&D integration from the perspective of pharmaceutical firms. More specifically, this report maps the direction and scale of genomics in determining drug development, drug markets, and drug-related business strategy over the coming decade.

The following key issues are among those evaluated by our panel and presented in this study:

  -- The impact of genomics technologies on the pharmaceutical,      biotechnology, diagnostics, and service sectors.   -- How genomics technologies will impact drug discovery, development, and      clinical trial design.   -- Current and projected pharmaceutical and other sector investments in      genomics.   -- Intellectual property and patentability issues, government involvement,      and ethical constraints.   -- The anticipated commercial impact of market segmentation on genomics-      based drug sales and the potential for blockbuster drugs in the post-      genomic era.   -- The pricing of genomics-based therapeutics.  

Overall, the industry executives interviewed in this study believe that genomics-based drugs will be safer, more efficacious, and possibly less expensive to develop than conventional drugs. The first disease markets to benefit from genomics will be cancer, central nervous system disorders, and infectious diseases. Compared with current drug development methods, genomics also offers the potential for developing drugs that affect a greater number and a wider variety of molecular targets. Successes in diversified drug target development will significantly impact traditional pharmaceutical markets. Markets will become more segmented as genomics-based drugs, pharmacogenomics, and genetic epidemiology address more-focused indications and patient populations. The ability to more narrowly define a disease target may also lead to a decrease in the number of blockbuster drugs in the industry. Conversely, it may expand the usage of particular drugs in other indications.

Genomics and Drug Development: Impacts and Strategic Implications is a Pharmacor Special Report published by Decision Resources, Inc.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries. Visit Decision Resources at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,

Decision Resources Study Evaluates Emerging Therapies to Serve the Allergic Rhinitis Population

View Now